C. Henderson

Adjuvant systemic therapy for early breast cancer

C. Henderson, 1994, Cancer.

Sensitivity of human multiple myelomas and myeloid leukemias to the proteasome inhibitor I

D. Delia, C. Brancolini, D. Soligo, 2005, Leukemia.

Cardiac safety of liposomal anthracyclines.

C. Shapiro, A. Gabizon, F. Martin, 2004, Seminars in oncology.

OF NORTH AMERICA New Directions in Breast Cancer Research and Therapeutics

C. Shapiro, C. Henderson, 2017 .

Cost-Benefit Analysis of Chemotherapy Trials

R. Gelman, C. Henderson, 1987 .

Established and emerging roles of liposomal anthracyclines in oncology. Introduction.

C. Henderson, 2004, Seminars in Oncology.

Adjuvant systemic therapy for early breast cancer

C. Henderson, 1994, Cancer.

Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials

Bingshu E. Chen, R. Gray, P. Lønning, 2023, The Lancet.

Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.

Richard L Schilsky, Larry Norton, James N Ingle, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial

S. Martino, R. Livingston, W. Barlow, 2009, The Lancet.

Adjuvant systemic therapy for early breast cancer.

I. Henderson, C. Henderson, 1987, Current Problems in Cancer.